Life sciences consulting M&A entered 2026 with real momentum, and boutique firms are the ones being bought. Equiteq's 2026 Life Sciences Consulting M&A Report puts a number on it: roughly 74% of acquired firms had fewer than 100 employees, and the median private market valuation sits at 14.5x EV/EBITDA, ahead of public market benchmarks. The market itself is growing at close to 9% CAGR through 2030, and deal activity is concentrated in North America and Western Europe, led by the US and UK.
It isn't abstract. Argano's acquisition of Pharosity Consulting, a life sciences-focused firm specialising in gross-to-net, government pricing and commercial consulting, is one recent example of exactly this pattern playing out. Smaller, highly specialised firms with a defensible niche are being folded into larger platforms at valuations that reward precisely the kind of focus a boutique consultancy builds over years.
Why boutique firms specifically
Acquirers aren't buying scale for its own sake. Private equity sponsors are, by CLA's read of the market, more selective than in prior cycles, prioritising fewer deals with clearer underwriting rather than broad platform building through volume. What they're paying for is capability that would take years to build organically: tech-enabled delivery, regulatory depth, CRO-adjacent expertise, and a client book in a specific therapeutic or functional niche. A boutique firm that has spent a decade becoming the trusted name in, say, market access pricing strategy is a shortcut to exactly that.
What it means if you're a Partner at a firm being acquired
An acquisition is often framed internally as validation, and it can be. It's also a genuine inflection point for anyone senior enough to have equity, influence, or a client book that the deal depends on. Reporting lines change, incentive structures get rebuilt around a new parent company's model, and the culture that made the firm worth buying doesn't always survive contact with a larger platform's processes.
An acquisition can be a strong signal of validation for a boutique firm, but it changes the deal for anyone joining or already there. The question worth asking isn't just what the firm looks like today, it's what it will look like eighteen months after the ink dries.
None of that makes an acquisition a bad thing to be part of. It does mean the due diligence runs both ways. A Partner considering a move to a firm that's recently been acquired, or already at one, is well served by asking direct questions about integration plans, retention structures, and how much operating autonomy actually survives the transition, before assuming the old version of the firm is still what's on offer.
What it means for firms staying independent
Competing against a rival that's just been recapitalised with PE backing changes the calculus. Newly acquired competitors can often move faster on hiring, technology investment and geographic expansion than they could as standalone boutiques. For firms with no interest in being acquired themselves, the practical response is usually the same one that made the acquired firms attractive in the first place: sharpen the niche, invest in the bench strength that supports succession, and make sure the firm's value doesn't rest entirely on one or two individuals who could be poached or could retire.